Treatment with MCC950 after stroke can reduce the expression of various proinflammatory cytokines and components of the NLRP3 inflammasome, thereby decreasing infarct volume in a dose-dependent manner [121]. The gene discussed is NLRP3; the disease is stroke disorder.